Perhaps or maybe the US govt might assist with some upfront costs, as they have done with another Covid therapeutic (sorry I am terrible at remembering names). There is also a case for another re-rating of SP - if SNG was listed on theNASDAQ. That could also help raise the necessary cash. Perhaps the more informed here might tell me if this idea has merit or is dead in the water!
Don't speak French but this is a translation courtesy of Google
News COVID-19: Phase III for a beta interferon to be inhaled at home
Research is advancing on new forms of COVID-19 treatment that are easy to follow at home. The AIDS Clinical Trials Group (ACTG) thus announces the passage of the experimental drug "SNG001", an inhaled formulation of beta interferon in a phase III clinical trial, within the framework of the research program "ACTIV-2", a supported program by the National Institute of Allergy and Infectious Diseases (NIAID / NIH).
ACTG is the world's largest HIV research network, but this program has recently expanded to include outpatient treatment evaluation for COVID-19. The phase III trial is to assess the effectiveness of an inhaled formulation of interferon beta in treating early symptomatic COVID-19 at home - or in out-of-hospital patients.
ACTIV-2 is the first trial to assess candidate SNG001, developed by Synairgen, a British university spin-off as an outpatient treatment for COVID-19. SNG001, a beta interferon - or natural cytokine promoting the antiviral response - is self-administered as a nebulized dose (15.6 MIU) taken once daily for 14 days. As part of the trial, the participants were trained in the use of the nebulizer by the researchers. 2 other treatments, BRII-196 / BRII-198 (a combined treatment with a monoclonal antibody) and SAB-185 (a new treatment with a polyclonal antibody) are also undergoing a phase III trial as part of the ACTIV- research program. 2.
Developing simple at-home treatment options
“This inhaled version of beta interferon expands possible treatment options for people with COVID-19 who are not hospitalized. If validated, such a treatment would simplify care for a large number of people with COVID-19 ”.
The phase III trial for SNG001 is to assess the safety and efficacy of the candidate in reducing the risk of hospitalization and death in non-hospitalized adults with mild to moderate forms of COVID-19. The study is being led by a team from the University of North Carolina and Stanford University.
An option that comes in addition to the antiviral pill from the Merck Laboratory in the process of "fast track" approval by the European Medicines Agency.
Across markets, round/whole numbers can be support/resistance because of the psychological effect. On the hourly chart, it can be seen that around the 200 mark, initially there was support but when this support breaks down, it in turn becomes resistance.
Hey-ho: just short term price dynamics in play. The bigger slight longer term picture is what is important and that is up!
RE: All boards look the same on a bit of upwards volatility25 Oct 2021 11:47
No worries, Ndn
I sometimes forget to explain my reasoning as well. My figure of initial target at 300-325 is based on several confluence price points from a charitist perspective. One is a Fibonacci extension, another is the ‘rule of thumb’ that follows a break out from a triangle consolidation: take the widest part of the triangle and project that from the breakout point.
I think I replied similarly to Raphaking recently
But ‘Gobble dee gook’ if you’re not into technical analysis.
We do have a few minor resistance lines to break first, but as other posters have said, we reached £258 last year so once this is breached, 300-325 is the FIRST target. Assuming good Sprinter results, I am expecting the SP to 'step-ladder' up, even allowing for 'gap-up'. Patience still required.